VolitionRx's Nu.Q Vet Assay Achieves 97% Specificity in Feline Lymphoma Detection

VolitionRx Limited (NYSE American: VNRX) has announced the submission of a clinical manuscript for peer review that demonstrates the high accuracy of its Nu.Q Vet Feline prototype assay in detecting lymphoma in cats. The assay achieved 97% specificity and identified 86% of lymphoma cases, marking a significant step forward in developing a blood-based liquid biopsy test for feline cancer. This technology addresses a critical unmet need in veterinary medicine, where non-invasive, early detection tools for cancer are scarce. The company sees this as a major commercial opportunity, with potential milestone payments and future revenue generation as it works toward product commercialization and expands its presence in the growing companion animal oncology market.

The publication of this study in a peer-reviewed journal is expected to unlock a $5 million contractual milestone payment for Volition. The company is a multinational organization focused on advancing the science of epigenetics, with a mission to save lives and improve outcomes for both humans and animals through earlier disease detection and monitoring. Through its subsidiaries, Volition develops simple, cost-effective blood tests to detect and monitor diseases such as cancer and sepsis. Its research and development activities are centered in Belgium, with additional offices in the U.S. and London.

This news was disseminated by BioMedWire (BMW), a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. BMW is part of the Dynamic Brand Portfolio @ IBN, which provides a range of services including press release distribution, editorial syndication to over 5,000 outlets, and social media distribution. For more details, visit the full press release at https://ibn.fm/ARsEY. Volition's website can be found at www.Volition.com.